跳至主要内容
临床试验/NCT02083289
NCT02083289已完成2 期

A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)

Ono Pharmaceutical Co. Ltd12 个研究点 分布在 1 个国家目标入组 123 人开始时间: 2014年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
123
试验地点
12
主要终点
Evaluating the safety parameters per protocol

研究概览

简要总结

The primary objectives of this study are to compare the safety, tolerability, and mean change from baseline in diurnal intraocular pressure (IOP) of ONO-9054 30 µg/mL (0.003%) to latanoprost 0.005% following ocular instillation once every evening for 28 days.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female aged 18-85 (inclusive) with confirmed diagnosis of OHT or OAG
  • Confirmed diagnosis of bilateral OHT or mild to moderate chronic OAG
  • Able to undergo washout of all ocular drugs
  • An IOP ≥ 24 mmHg at 8:00 AM and ≥ 21 mmHg at 10:00 AM in at least 1 eye; but < 36 mmHg in both eyes at both Day -5 and Day 1
  • Central corneal thickness 500-620 µm at screening and Day -5 in both eyes
  • Best corrected visual acuity (BCVA) of +0.7 Log Mar or better

排除标准

  • Any history of severe ocular trauma in either eye at any time
  • History of angle closure or ocular laser surgery within the past 3 months or any refractive surgery procedure within the past 6 months of Screening Visit in the study eye(s)
  • Cataracts that prevent observation or photography of the fundus in either eye

研究组 & 干预措施

Experimental Arm 1

Experimental

ONO-9054 eye drop solution, 30 µg/mL (0.003%), once daily in both eyes, for 28 days.

干预措施: ONO-9054 (Drug)

Active Comparator Arm 2

Active Comparator

Latanoprost eye drop solution, 0.005%, once daily in both eyes for 28 days.

干预措施: Latanoprost (Drug)

结局指标

主要结局

Evaluating the safety parameters per protocol

时间窗: 28 days

Physical and ocular examinations (tolerability, hyperemia, visual acuity, pupillometry, corneal thickness, aqueous cells and flare), vital signs, and safety laboratory evaluations

Mean change in diurnal IOP (average of four time points) from baseline

时间窗: 28 days

次要结局

  • Diurnal IOP(28 days)
  • Mean change from baseline in IOP at each measured time point(28 days)
  • Treatment response rates(28 days)
  • Percent change from baseline in IOP at each measured time point(28 days)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (12)

Loading locations...

相似试验

A 28 Day Study of ONO-9054 Ophthalmic Solution in... | 临床试验